Motac Neuroscience Ltd.

What Motac Neuroscience Ltd. does

Motac Neuroscience Ltd. is a privately held contract research organization founded in 1999, headquartered at Motac France Sarl in Floirac, France, with additional operations in Manchester, United Kingdom and an affiliate in Beijing, China. The company provides highly specialized preclinical research services, principally in vivo and ex vivo studies, to pharmaceutical and biotechnology clients developing therapeutics for central nervous system disorders, with a particular concentration on Parkinson's disease, other movement disorders, and disorders of cognition. Its core capabilities include state-of-the-art rodent and non-human primate (NHP) model systems with high translational validity, neurohistology, immunohistochemistry, neurochemistry, and in vivo calcium imaging delivered through a partner ecosystem that includes Cynbiose (NHP/France), Inscopix (imaging), HZ-Bio (NHP/China), Life Biosciences (China), and NeuronExperts (in vitro/France).

The business model is professional services revenue, with engagements ranging from simple fee-for-service studies to risk-sharing collaborations, supplemented by an intellectual property portfolio covering novel chemical entities and therapeutic targets for movement disorders, including a composition-of-matter patent on dopamine D3 receptor agonists for Parkinson's Disease. Senior scientific staff bring over 300 years of combined active research experience in movement disorders, neuropsychology, and cognition, and the company participates in EU-funded consortia (NEXGEN, AND-PD, PARMED) alongside academic and private-sector collaborators. Go-to-market is direct enterprise sales to pharma and biotech, with no public pricing or named end-customer disclosure available in the source material.

The company is led by Erwan Bezard, PhD, who serves as Chief Executive & Scientific Officer and also appears on the legal notice as Publication Manager and Data Protection Officer. Motac operates as an independent private entity with no disclosed venture or private equity funding, no parent company, no subsidiaries, and no M&A activity on record.

Name

Motac Neuroscience Ltd.

Legal name

Motac France Sarl

Website

https://motac.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Short description

Motac Neuroscience Ltd. is a privately held preclinical contract research organization providing specialized in vivo and ex vivo neuroscience research services to pharmaceutical and biotechnology clients developing treatments for Parkinson's disease, movement disorders, and cognitive disorders.

Ownership category

akta.pro rank

Product category

Preclinical Contract Research Services

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Preclinical research services
• Contract research organization
• Neurodegenerative disease models
• CNS drug development
• Parkinson's disease research

Headquarters

HQ city

Manchester

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Contract Research Services: Fee-for-service preclinical research contracts ranging from simple studies to risk-sharing collaborations. Services provided include laboratory-based research in state-of-the-art rodent and NHP facilities, expert consultancy, and study design services for pharmaceutical and biotechnology clients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Motac Neuroscience provides highly-specialised preclinical contract research services for the pharmaceutical and biotechnology industries, supporting the discovery and development of therapeutics for neurological and psychiatric disorders. Core offerings include in vivo and ex vivo studies, state-of-the-art rodent and NHP model systems for Parkinson's disease and other movement and cognitive disorders, neurohistology, immunohistochemistry, neurochemistry, and in vivo calcium imaging, complemented by expert scientific consultancy and an IP portfolio around dopamine D3 receptor agonists.

Product overview

Motac Neuroscience Ltd. offers a unified portfolio of preclinical contract research services for the pharmaceutical and biotechnology industries, specializing in central nervous system drug development. The core offering consists of in vivo and ex vivo services, state-of-the-art model systems (including models of proteinopathies such as Parkinson’s disease, MSA, AD, PSP, HD and ALS, as well as movement and cognitive disorders), neurohistology, immunohistochemistry, neurochemistry, and in vivo calcium imaging. These services are complemented by expert scientific consultancy for study design and an intellectual property portfolio protecting novel dopamine D3 receptor agonists for Parkinson’s disease treatment.

Differentiator

Problem solved

Functional benefit

Products and services

• In Vivo and Ex Vivo Preclinical Services Wide range of highly-specialised in vivo and ex vivo preclinical services supporting the development of new treatments for neurodegenerative disorders, including Parkinson's disease, other movement disorders, and disorders of cognition, sold to pharmaceutical and biotechnology clients.
• Model Systems for Neurodegenerative Disorders State-of-the-art preclinical model systems with excellent translational validity including acute and progressive models of neurodegeneration, Parkinson's disease models, drug-induced dyskinesias models, and cognitive performance models, used by pharma and biotech sponsors to demonstrate efficacy of novel therapeutic approaches.
• Expert Scientific Consultancy Services Expert scientific consultancy for study design, protocol development, model selection, and scientific endpoints, offered alongside fee-for-service and risk-sharing preclinical research collaborations to pharmaceutical and biotechnology clients.
• Novel Dopamine D3 Receptor Agonists IP Program Intellectual property portfolio of worldwide patents and patent applications covering novel dopamine D3 receptor agonists for Parkinson's disease treatment, developed through strategic alliances and partnerships with industry collaborators.

Quantifiable outcome

• Expert consultancy services available for study design, model selection, scientific endpoints, and protocol design
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core.

• CynbiosecoreStrategic or Co-development PartnerCynbiose is a preclinical contract research organization based in France specializing in non-human primate models for biomedical research. Partnership provides scientific and technical continuity for product development in neurology, from rodents to primates. Includes continuous in-life preclinical package, unique scientific and technical CNS expertise, high QMS standards, and EU and AAALAC animal welfare standards. Cynbiose operates a 3000 sqm state-of-the-art primate animal facility (BSL 1-3) opened in 2024.
• InscopixcoreTechnology or IntegrationPartnership with Inscopix for neural network activity assessment through in vivo calcium imaging. Combines cutting-edge neural network functional information in relevant animal models such as Parkinson's disease, schizophrenia, multiple system atrophy, and Huntington's disease. Inscopix technology provides direct, real-time neural circuitry data at single cell resolution from hundreds to thousands of neurons, capturing powerful longitudinal information for acute drug-neural activity response and disease progression monitoring.
• HZ-Bio (HuaZen Biosciences)coreStrategic or Co-development PartnerPartnership to offer NHP models of spontaneous diabetes, impaired glucose tolerance, obesity, dyslipidemia, osteoporosis and other diseases such as glaucoma and age-related macular degeneration. HZ-Bio is a subsidiary of Huazhen Laboratory Animal Breeding Center, an AAALAC accredited facility with more than 32,000 Macaca fascicularis (cynomolgus monkeys) with over 20 years of experience. Operates a state-of-art NHP vivarium with 14 study rooms, 2 surgery rooms, more than 500 single cages, and over 20 group cages with imaging and biochemistry capabilities.
• Life BiosciencescoreStrategic or Co-development PartnerPartnership with Life Biosciences China to offer pharmacology and efficacy studies, pharmacokinetics, early toxicity, and GLP tox studies. Life Biosciences is committed to being China's first scientific research provider integrating the whole CNS industry chain of experimental model resources, with operations in Beijing and Shenzhen.
• NeuronExpertscoreStrategic or Co-development PartnerPartnership with NeuronExperts, a leading French contract research organization specializing in neuronal cell cultures and neuropharmacology. Offers extensive expertise in primary neuronal models to evaluate neuro-active compounds with tailored consulting, research, and development solutions. Enables seamless workflow from early-stage compound screening to advanced preclinical validation, enhancing predictability and translational value in drug development.
• AND-PD (Anxiety and Parkinson's Disease Project)coreStrategic or Co-development PartnerAND-PD project investigates the impact of Parkinson's Disease on pathways in the brain to further understand the functional and pathological changes caused by the disease. This EU-funded research collaboration aims to investigate comorbidity mechanisms of anxiety and Parkinson's Disease.
• NEXGEN (Parkinson's Disease Research Project)coreStrategic or Co-development PartnerNEXGEN is a Horizon Europe Research and Innovation Project aiming to revolutionize treatment and diagnosis of Parkinson's Disease. The project pioneers a new vaccine platform producing substantially stronger immune responses than existing vaccines and develops a new diagnostic assay to detect biomarkers of Parkinson's in blood and urine for earlier detection.
• PARMED (RNA Therapies Project)coreStrategic or Co-development PartnerPARMED is a groundbreaking project developing disease-modifying RNA therapies for Parkinson's Disease in collaboration with Neumirna Therapeutics (Denmark), University of Bordeaux (France), and the Center of RNA Medicine at Aalborg University (Denmark).

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• Psychogenics: US-based preclinical CRO specializing in CNS disease models and behavioral phenotyping. Closely comparable to Motac in deep CNS specialization, in vivo behavioral readouts, and pharma/biotech sponsor base for neurodegeneration and psychiatry programs.
• QPS Holdings: Global CRO with a strong neuroscience and DMPK preclinical practice serving pharma and biotech. Overlaps with Motac on CNS efficacy, safety, and translational pharmacology, and competes for similar outsourced preclinical CNS work.
• Biotrial: European CRO offering preclinical and clinical neuroscience services, including CNS drug development. Comparable to Motac in CNS-focused preclinical capabilities and proximity to European pharma sponsors.
• Crown Bioscience: Preclinical CRO with oncology and metabolic disease models and growing neuroscience capabilities. Comparable as a translational CRO serving pharma/biotech with in vivo efficacy studies and disease models.
• Sygnature Discovery: UK-headquartered drug discovery CRO with in vivo pharmacology and CNS expertise. Comparable geography and service mix to Motac, and serves a similar pharma/biotech buyer for CNS discovery and preclinical programs.

Broad incumbents

• Charles River Laboratories: Large global CRO providing safety assessment, DMPK, and preclinical research including CNS models. Broader portfolio and global scale, but overlapping on the preclinical CNS efficacy and safety work Motac provides.
• Labcorp Drug Development (incl. Covance and Early Development): Global CRO offering early development, preclinical, and central lab services including CNS pharmacology. Competes with Motac for outsourced preclinical CNS work as part of integrated discovery-to-IND packages.
• WuXi AppTec: China-headquartered global CRO/CDMO with extensive preclinical and discovery services, including in vivo pharmacology. Overlaps with Motac through partnerships in China (Life Biosciences, HZ-Bio) and broader CNS drug development demand.
• Eurofins Discovery: Discovery and preclinical CRO covering in vitro and in vivo pharmacology, including CNS indications. Provides broader service portfolio than Motac but addresses the same outsourced CNS preclinical needs.
• Inotiv: Preclinical CRO and research models provider with in vivo pharmacology and safety services. Comparable on the animal-model-driven preclinical side, particularly for CNS and metabolic disease research programs.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/motac-neuroscience-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Motac Neuroscience Ltd.